Table 1.
Patient characteristics and univariate Cox regression analysis for lymphocyte nadir during radiotherapy
| Characteristic | All Patients (n=178) | Lymphocyte Nadir during Radiotherapy | Hazard | P Value | |
|---|---|---|---|---|---|
| >0.3×109/L (n=76) | <0.3×109/L (n=102) | Ratio (95% CI) | |||
| Age, years | |||||
| Median (range) | 66 (37–85) | 65 (37–81) | 66 (39–85) | 1.025 (1.004–1.046) | |
| 0.020 | |||||
| Mean (SD) | 64.7 (9.2) | 63.4 (9.7) | 65.8 (8.6) | ||
| Sex, no. (%) | |||||
| Female | 83 (46.6) | 34 (19.1) | 49 (27.5) | 1.00 | |
| Male | 95 (53.4) | 42 (23.6) | 53 (27.8) | 0.873 (0.592–1.2089) | |
| 0.495 | |||||
| Smoking pack-years | |||||
| Median (range) | 43 (0–244) | 37 (0–125) | 48 (0–244) | 1.003 (0.999–1.007) | |
| 0.150 | |||||
| Mean (SD) | 50.0 (39.8) | 43.9 (30.7) | 54.5 (44.9) | ||
| Tumor histology | |||||
| Squamous | 62 (34.8) | 25 (14.0) | 37 (20.8) | 1.00 | |
| Adeno | 92 (51.7) | 36 (20.2) | 56 (31.5) | 1.017 (0.671–1.541) | |
| 0.938 | |||||
| Other | 24 (13.5) | 15 (8.4) | 9 (5.1) | 0.542 (0.261–1.124) | |
| 0.100 | |||||
| GTV, cm3 | |||||
| Median (range) | 77.7 (1.9–686.6) | 55.5 (1.9–686.6) | 108.1 (5.7–673.7) | 1.001 (1.000–1.003) | |
| 0.030 | |||||
| Mean (SD) | 132.7 (136.4) | 118.8 (140.5) | 142.8 (133.1) | ||
| Disease stage, no. (%)* | |||||
| IIA-IIB | 12 (6.7) | 5 (2.8) | 7 (3.9) | 1.000 | |
| IIIA-IIIB | 152 (85.4) | 63 (35.4) | 89 (50) | 1.196 (0.553–2.584) | |
| 0.649 | |||||
| IV+recurrent | 14 (7.9) | 8 (4.5) | 6 (3.4) | 0.743 (0.249–2.214) | |
| 0.593 | |||||
| Tumor location | |||||
| LLL+RLL+RML | 53 (29.8) | 23 (12.9) | 30 (16.8) | 1.000 | |
| LUL+RUL | 116 (65.2) | 48 (27.0) | 68 (38.2) | 0.795 (0.280–2.260) | |
| 0.667 | |||||
| Mediastinum | 9 (5.1) | 5 (2.8) | 4 (2.2) | 1.052 (0.683–1.622) | |
| 0.818 | |||||
| KPS, no. (%) | |||||
| 90 | 56 (31.5) | 21 (11.8) | 35 (19.7) | 1.000 | |
| 80 | 109 (61.2) | 50 (28.1) | 59 (33.1) | 0.959 (0.444–2.072) | |
| 0.916 | |||||
| 70 | 13 (7.3) | 5 (2.8) | 8 (4.5) | 0.851 (0.406–1.873) | |
| 0.669 | |||||
| XRCC1 rs25487 | |||||
| AA | 42 (23.6) | 9 (5.1) | 33 (18.5) | 1.065 (1.089–2.500) | |
| 0.018 | |||||
| AG | 80 (44.9) | 43 (24.2) | 37 (20.8) | — | — |
| GG | 56 (31.5) | 24 (13.5) | 32 (18.0) | — | — |
| AG+GG | 136 (76.4) | 67 (37.6) | 69 (38.8) | 1.000 | |
| ALC at baseline (x109 cells/L) | |||||
| Median (range) | 1.63 (0.3–4.12) | 1.81 (0.3–3.62) | 1.48 (0.39–4.12) | 0.832 (0.624–1.109) | |
| 0.210 | |||||
| Mean (SD) | 1.77 (0.72) | 1.82 (0.69) | 1.72 (0.74) | ||
| Radiation modality | |||||
| Photons | 114 (64.0) | 47 (26.4) | 67 (37.6) | 1.000 | |
| Protons | 64 (36.0) | 29 (16.3) | 35 (19.7) | 0.792 (0.526–1.193) | |
| 0.265 | |||||
| Induction chemo, no. (%) | |||||
| No | 114 (64.0) | 50 (28.1) | 64 (36.0) | 1.000 | |
| Yes | 64 (36.0) | 26 (14.6) | 38 (21.3) | 1.128 (0.755–1.686) | |
| 0.557 | |||||
| Lung V5, % | <0.0001 | ||||
| Median (range) | 48.18 (12.3–89.4) | 43.84 (18.6–73.9) | 52.04 (12.3–89.4) | 1.031 (1.017–1.045) | |
| <0.001 | |||||
| Mean (SD) | 48.4 (14.1) | 45.3 (13.3) | 50.7 (14.3) | ||
| Mean lung dose, Gy | |||||
| Median (range) | 17.8 (1–22.8) | 16.0 (1–22.8) | 18.5 (1–22.7) | 1.073 (1.023–1.126) | |
| 0.004 | |||||
| Mean (SD) | 16.9 (4.3) | 16.3 (4.5) | 17.6 (3.8) | ||
| Heart V5, % | |||||
| Median (range) | 38.1 (0–100) | 29.5 (0–99.6) | 46 (0–100) | 1.013 (1.005–1.020) | |
| 0.001 | |||||
| Mean (SD) | 43.4 (27.6) | 37.8 (26.0) | 47.7 (28.2) | ||
| Mean heart dose, Gy | |||||
| Median (range) | 8.4 (0–37.0) | 5.8 (0–37.0) | 10.2 (0–34.6) | 1.028 (1.007–1.049) | |
| 0.009 | |||||
| Mean (SD) | 10.8 (9.0) | 9.3 (9.1) | 12.0 (8.8) | ||
Abbreviations: CI, confidence interval; SD, standard deviation; GTV, gross tumor volume; KPS, Karnofsky performance status score; LLL, left lower lobe; RLL, right lower lobe; RML, right middle lobe; LUL, left upper lobe; RUL, right upper lobe; ALC, absolute lymphocyte count.
*
AJCC 6th edition.